FDA Approved89% Match

Osimertinib + Bevacizumab Combination

EGFR Targeted Therapy + Anti-angiogenic

Combination of Osimertinib (3rd generation EGFR inhibitor) with Bevacizumab (anti-VEGF antibody) for EGFR-mutated non-small cell lung cancer.

How It Works

Osimertinib blocks mutated EGFR proteins while Bevacizumab prevents new blood vessel formation to tumors. This dual approach attacks cancer cells directly while cutting off their blood supply.

Clinical Trial Results

Trial Phase:Phase III (Approved)

Patient Count:449 patients

Response Rate:74%

PFS:18.9 months

Overall Survival:24.5 months

Side Effects Profile

Personalized for Your Profile

Your EGFR mutation type suggests good response probability with manageable skin-related side effects.

Common Side Effects

Skin rash (58%)
Diarrhea (46%)
Fatigue (31%)
Hypertension (28%)

Serious Side Effects

Interstitial lung disease (2%)
Bleeding events (5%)
Heart problems (3%)

How to Access This Treatment

EGFR Testing Confirmation

Verify EGFR mutation status with updated tumor testing

Expected timeframe: 1 week

Insurance Authorization

Submit prior authorization request to insurance provider

Expected timeframe: 1-2 weeks

Baseline Testing

Complete heart function and organ assessment tests

Expected timeframe: 1 week

Treatment Start

Begin combination therapy at oncology center

Expected timeframe: 1 week

Quick Facts

AvailabilityAvailable Now

Estimated Cost$18,000-22,000/month

InsuranceMost major insurers

RegionsUS, EU, Asia-Pacific

Eligibility Criteria

EGFR mutation positive (exon 19 deletion or L858R)
Advanced or metastatic NSCLC
No prior EGFR inhibitor therapy (first-line)
Adequate cardiac and organ function
No recent bleeding events

Take Action

Demo Notice: Treatment information shown is for demonstration purposes. Real clinical data integration and AI analysis are not yet implemented.